TTLL12

TTLL12 is an atypical member of the tubulin tyrosine ligase-like family that functions as a pseudo-enzyme, exerting its cellular roles through direct protein–protein interactions rather than the methyltransferase or tubulin tyrosine ligase activities predicted from its sequence (PMID:28011935, PMID:38394155). In innate immunity, cytosolic TTLL12 acts as a negative regulator of RIG-I-mediated antiviral signaling by binding directly to VISA/MAVS, TBK1, and IKKε and disrupting VISA's association with downstream signaling partners, dampening interferon-β induction independently of any catalytic activity (PMID:28011935). At the cytoskeleton, TTLL12 binds the α/β-tubulin heterodimer directly and localizes to the base of primary cilia, where it is required for ciliogenesis in polarized renal epithelial cells; rather than adding glutamate or glycine to tubulin tails like canonical TTLL enzymes, it promotes microtubule lysine acetylation and arginine methylation and modulates microtubule dynamics and stability (PMID:38177908, PMID:37546873). TTLL12 additionally suppresses ligation of nitrotyrosine onto detyrosinated α-tubulin, reducing tubulin nitrotyrosination in cells (PMID:38394155). These tubulin-related and signaling activities converge on pro-tumorigenic functions: TTLL12 enhances cancer cell survival and proliferation (PMID:33123251), drives an immunosuppressive tumor microenvironment by promoting CCL9 transcription and recruitment of myeloid-derived suppressor cells (PMID:40461158), and stabilizes eEF1A1 by competing with BPOZ-2 to block CUL3-mediated ubiquitin-proteasome degradation, thereby promoting hepatocellular carcinoma cell proliferation (PMID:42014684).

1. 2016 High

   Established the first defined molecular function for TTLL12 as a cytosolic brake on antiviral innate immune signaling, answering whether this predicted enzyme has a non-cytoskeletal role.

   Evidence Reciprocal Co-IP, cell fractionation, CRISPR/RNAi knockdown with IFN-β phenotype, and Sendai virus infection assays, plus mutagenesis testing enzymatic dependency

   PMID:28011935

   Open questions at the time

   • Structural basis of how TTLL12 disrupts VISA's interactions is undefined
   • Whether this immune role is shared across cell types is not addressed
   • No direct demonstration of catalytic inactivity, only mutagenesis inference
2. 2023 High

   Resolved whether TTLL12 acts on microtubules like other TTLL family members, showing it binds tubulin directly but promotes atypical PTMs and is required for ciliogenesis.

   Evidence In vitro tubulin-binding assay, localization imaging, loss-of-function in polarized renal epithelial cells, and acetylation/arginine-methylation PTM readouts

   PMID:37546873 PMID:38177908

   Open questions at the time

   • Whether TTLL12 directly catalyzes acetylation/methylation or recruits other enzymes is unresolved
   • Mechanism linking microtubule PTM changes to cilium assembly not detailed
   • Connection to the immune-signaling role is not established
3. 2020 Medium

   Linked TTLL12 to cancer cell survival, showing it protects cells from nitrotyrosine stress and supports proliferation.

   Evidence Gain- and loss-of-function SCC-25 cell lines with western blot, immunofluorescence, and MTT proliferation assay

   PMID:33123251

   Open questions at the time

   • Single lab, limited mechanistic depth on how nitration protection drives survival
   • No in vivo confirmation in this study
   • Tubulin nitration detection not reconstituted biochemically
4. 2024 Medium

   Defined a specific biochemical output of TTLL12's pseudo-enzymatic action—suppression of tubulin nitrotyrosination—and converted it into a screening readout.

   Evidence TTLL12 overexpression with cell-based ELISA for nitrotyrosinated α-tubulin and high-throughput compound screening

   PMID:38394155

   Open questions at the time

   • No direct in vitro reconstitution of the suppression mechanism
   • Whether suppression is via competition for tubulin C-terminus or another route is unclear
   • Single-lab overexpression assay only
5. 2025 Medium

   Connected tumor-intrinsic TTLL12 to immune evasion via a transcriptional/chemokine axis recruiting suppressive myeloid cells.

   Evidence Gain/loss-of-function in syngeneic mouse models, flow cytometry, MDSC migration/proliferation assays, ChIP and mass spectrometry implicating CCL9 promoter binding

   PMID:40461158

   Open questions at the time

   • Direct DNA-binding versus indirect promoter recruitment not firmly distinguished
   • How a cytosolic/microtubule-associated protein engages chromatin is mechanistically unexplained
   • Single lab, not independently replicated
6. 2026 Medium

   Identified a protein-stabilization mechanism whereby TTLL12 promotes oncogenesis by shielding eEF1A1 from ubiquitin-proteasome degradation.

   Evidence Co-IP mapping TTLL12/BPOZ-2/eEF1A1 interactions, ubiquitin-proteasome degradation assays, knockdown/overexpression proliferation readouts, and in vivo tumor models

   PMID:42014684

   Open questions at the time

   • Single lab, not yet independently replicated
   • Competition stoichiometry and binding interface with BPOZ-2 undefined
   • Relationship to TTLL12's tubulin and immune roles unknown

• Whether TTLL12's diverse activities (immune signaling, microtubule PTMs, transcription, protein stabilization) reflect one unifying biochemical mechanism or independent moonlighting functions remains unresolved.
• No structural model explaining how a single pseudo-enzyme engages tubulin, signaling adaptors, chromatin, and eEF1A1
• No reconciliation of cytosolic versus ciliary-base versus nuclear localizations
• No direct evidence of any catalytic activity for TTLL12